EP4322931A4 - Transdermale verabreichung von cannabidiol - Google Patents

Transdermale verabreichung von cannabidiol

Info

Publication number
EP4322931A4
EP4322931A4 EP22787716.4A EP22787716A EP4322931A4 EP 4322931 A4 EP4322931 A4 EP 4322931A4 EP 22787716 A EP22787716 A EP 22787716A EP 4322931 A4 EP4322931 A4 EP 4322931A4
Authority
EP
European Patent Office
Prior art keywords
cannabidiol
transdermal administration
transdermal
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP22787716.4A
Other languages
English (en)
French (fr)
Other versions
EP4322931A1 (de
Inventor
Fotios M. Plakogiannis
Tamanna LATHER
Nisarg MODI
Marina BOROVINSKAYA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pike Therapeutics Inc
Original Assignee
Pike Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/227,591 external-priority patent/US12121617B2/en
Application filed by Pike Therapeutics Inc filed Critical Pike Therapeutics Inc
Publication of EP4322931A1 publication Critical patent/EP4322931A1/de
Publication of EP4322931A4 publication Critical patent/EP4322931A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP22787716.4A 2021-04-12 2022-04-07 Transdermale verabreichung von cannabidiol Withdrawn EP4322931A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17/227,591 US12121617B2 (en) 2019-10-14 2021-04-12 Transdermal delivery of cannabidiol
PCT/IB2022/053276 WO2022219468A1 (en) 2021-04-12 2022-04-07 Transdermal delivery of cannabidiol

Publications (2)

Publication Number Publication Date
EP4322931A1 EP4322931A1 (de) 2024-02-21
EP4322931A4 true EP4322931A4 (de) 2025-03-12

Family

ID=83640369

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22787716.4A Withdrawn EP4322931A4 (de) 2021-04-12 2022-04-07 Transdermale verabreichung von cannabidiol

Country Status (7)

Country Link
EP (1) EP4322931A4 (de)
JP (1) JP2024513961A (de)
CN (1) CN117460503A (de)
AU (1) AU2022257344A1 (de)
CA (1) CA3214228A1 (de)
MX (1) MX2023011948A (de)
WO (1) WO2022219468A1 (de)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170071870A1 (en) * 2015-09-14 2017-03-16 Life Tech Global, Llc Transdermal Delivery of Cannabidiol with Other Active Moieties Including Cannabinoids
US20190133994A1 (en) * 2014-04-18 2019-05-09 Mm Technology Holdings, Llc Transdermal Cannabinoid Patch
WO2019140321A1 (en) * 2018-01-12 2019-07-18 Nutrae, LLC Encapsulated cannabinoid formulations for transdermal delivery
WO2021074790A1 (en) * 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal delivery of cannabidiol

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5801794B2 (ja) * 2009-04-28 2015-10-28 ジネルバ ファーマシューティカルズ， インコーポレイティド カンナビジオールの製剤及びその使用方法
AU2009345154A1 (en) * 2009-04-29 2011-12-22 University Of Kentucky Research Foundation Cannabinoid-containing compositions and methods for their use
HUE034235T2 (en) * 2009-08-31 2018-02-28 Zynerba Pharmaceuticals Inc Use of cannabidiol prodrugs in topical and transdermal delivery with microdisks
AU2018318425A1 (en) * 2017-08-14 2020-02-27 Zynerba Pharmaceuticals, Inc. Methods of treatment of osteoarthritis with transdermal cannabidiol gel
US12357604B2 (en) * 2017-09-22 2025-07-15 Inmed Pharmaceuticals Inc. Topical formulations of cannabinoids and use thereof in the treatment of pain
AU2020325925B2 (en) * 2019-08-05 2025-05-29 Cs Medica A/S Topical formulations comprising cannabidiol, method of preparing the composition and use thereof
EP4110325A4 (de) * 2020-04-20 2024-07-03 Pike Therapeutics, Inc. Transdermale und/oder topische pharmazeutische formulierungen mit cannabidiol und/oder tetrahydrocannabinol zur behandlung chronischer schmerzen
CN116075296A (zh) * 2020-07-01 2023-05-05 长矛治疗股份有限公司 用于治疗多发性硬化症的透皮药物制剂
AU2021328741A1 (en) * 2020-08-17 2023-02-02 Pike Therapeutics, Inc. Pharmaceutical compositions and methods for treating Parkinson's disease
MX2023006561A (es) * 2020-12-03 2023-07-06 Pike Therapeutics Inc Formulaciones farmaceuticas transdermicas que comprenden cbd o thc para el tratamiento del cancer.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190133994A1 (en) * 2014-04-18 2019-05-09 Mm Technology Holdings, Llc Transdermal Cannabinoid Patch
US20170071870A1 (en) * 2015-09-14 2017-03-16 Life Tech Global, Llc Transdermal Delivery of Cannabidiol with Other Active Moieties Including Cannabinoids
WO2019140321A1 (en) * 2018-01-12 2019-07-18 Nutrae, LLC Encapsulated cannabinoid formulations for transdermal delivery
WO2021074790A1 (en) * 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal delivery of cannabidiol

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2022219468A1 *

Also Published As

Publication number Publication date
CA3214228A1 (en) 2022-10-20
AU2022257344A1 (en) 2023-10-26
CN117460503A (zh) 2024-01-26
JP2024513961A (ja) 2024-03-27
EP4322931A1 (de) 2024-02-21
MX2023011948A (es) 2023-10-17
WO2022219468A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
EP4045024A4 (de) Transdermale verabreichung von cannabidiol
EP4125902A4 (de) Transdermale verabreichung von dextromethorphan
EP4196114A4 (de) Transdermale pharmazeutische formulierungen von cannabinoiden
EP4135712A4 (de) Transdermale mikrodosierung von psychedelikaderivaten
EP4149460C0 (de) Feste therapeutische darreichungsformen
IL264644B (en) Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
DK3273942T3 (da) Mikronåleplaster til indgivelse af en aktiv bestanddel til huden
LT4331584T (lt) Lanifibranoro deuterintų darinių terapietiniai naudojimai
EP4240365A4 (de) Formulierungen zur transdermalen verabreichung
EP3946316A4 (de) Pharmazeutische cannabidiolzusammensetzungen
EP3731832A4 (de) Darreichungsform von cannabidiol
EP4415708A4 (de) Zusammensetzungen zur verabreichung von cannabinoiden
EP3485886A4 (de) Orale pharmazeutische zusammensetzung aus tecovirimat und herstellungsverfahren dafür
EP4377461A4 (de) Strukturbasierter entwurf von antisense-oligonukleotidarzneimitteln
IL285765A (en) Therapeutic uses of dulaglutide
EP4081206A4 (de) Herstellung von cannabichromen und verwandten cannabinoiden
EP4225129A4 (de) Oct-geführte therapie
EP4434969A4 (de) Anti-sars-cov-2-arzneimittel
EP4419131A4 (de) Orale verabreichung von therapeutischen mitteln
LT3880186T (lt) Pd-1 inhibitorių skyrimas į pažeidimo vietą odos vėžiui gydyti
HUE058114T2 (hu) Cediranib rögzített idõszakos adagolását tartalmazó eljárások
EP4398876A4 (de) Enterale aerobisationstherapie
IL311473A (en) Ophthalmic pharmaceutical compositions of roflumilast
EP4322931A4 (de) Transdermale verabreichung von cannabidiol
EP3917507A4 (de) Tumeszenzinfiltrationsarzneimittelabgabe von cannabinoiden

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20231108

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20240318

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20250212

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20250206BHEP

Ipc: A61K 47/14 20170101ALI20250206BHEP

Ipc: A61K 47/12 20060101ALI20250206BHEP

Ipc: A61K 47/10 20170101ALI20250206BHEP

Ipc: A61K 31/00 20060101ALI20250206BHEP

Ipc: A61P 29/00 20060101ALI20250206BHEP

Ipc: A61K 9/70 20060101ALI20250206BHEP

Ipc: A61K 9/00 20060101ALI20250206BHEP

Ipc: A61K 31/05 20060101AFI20250206BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20250905